Saniona AB: Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

PRESS RELEASE December 28, 2021 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet

Related Keywords

Australia ,United States ,New Zealand ,Denmark ,Copenhagen ,Køavn ,Stockholm ,Sweden ,United Kingdom ,Massachusetts ,Boston ,Italy ,Spain ,Trista Morrison ,Paige Rivard ,Rudolf Baumgartner ,Merling Butler ,University Of Kansas Medical Center ,International Prader Willi Syndrome Organisation ,Trial Initiation Press ,Foundation For Prader Willi Research ,Prader Willi Syndrome Association United States ,Head Of Clinical Development At Saniona ,Behavioral Sciences ,Division Of Research ,Chief Medical Officer ,Clinical Development ,Hyperphagia Questionnaire ,Clinical Trials ,Prader Willi Syndrome Association United ,Kansas Medical ,Prader Willi Research ,Chief Communications Officer ,Nasdaq Stockholm Small ,Prader Willi Syndrome ,Initiation Press ,Saniona ,Nitiates ,Hase ,Linical ,Trial ,Tesomet ,Trader ,Hilli ,Yndrome ,